12:00 AM
 | 
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Symbicort budesonide/formoterol: Post-marketing study data

Pooled data from 7,042 patients in 7 trials showed that inhaled budesonide with or without formoterol had no significant impact on the 1-year risk of pneumonia vs. placebo or formoterol alone (3% vs. 3% adverse event rate and 1%...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >